The National Institutes of Health is the largest non-defense funder of SBIR/STTR awards in the U.S. government, and for health and life-science founders it is the single most important non-dilutive funding source to understand. If you're building diagnostics, therapeutics, medical devices, digital health, research tools, or biotech platforms, NIH SBIR/STTR can fund the science you need to de-risk - without taking equity.
This page covers how NIH structures its small business programs, the two ways you can apply (omnibus vs targeted), typical budgets and durations, eligibility, clinical-trial considerations, and the realistic timeline.
What NIH SBIR/STTR funds
NIH's mission is health, so every funded project must have a credible path to improving health or advancing biomedical research. Within that, the scope is enormous because NIH is made up of many institutes and centers (cancer, aging, mental health, drug abuse, allergy and infectious disease, and more), each with its own priorities and budget.
Common categories of NIH SBIR/STTR work include:
- Therapeutics - small molecules, biologics, gene and cell therapies
- Diagnostics and devices - assays, imaging, point-of-care and wearable devices
- Digital health - software, AI/ML clinical tools, decision support
- Research tools and platforms - reagents, instruments, model systems
- Behavioral and public-health interventions
Like all SBIR/STTR, the funding is a grant (mostly the R43/R44 SBIR and R41/R42 STTR mechanisms): no equity, no repayment.
Omnibus vs targeted solicitations
There are two doors into NIH SBIR/STTR, and choosing the right one matters.
The omnibus (Parent) solicitation
The omnibus - also called the Parent solicitation - is broad and investigator-initiated. You propose whatever health-relevant project you believe in, as long as it fits within the mission of at least one NIH institute. This is where most first-time applicants start because it offers the widest latitude and predictable, recurring due dates.
Targeted solicitations (NOFOs)
Individual NIH institutes also publish targeted Notices of Funding Opportunity for specific topics they want pursued - say, a particular cancer detection method or addiction-treatment technology. These often come with set-aside funds and sometimes use contracts (with defined deliverables) instead of grants. If your work matches a targeted NOFO, it can be a stronger, more focused path - but the topic and requirements are fixed by NIH.
Tip: Before writing anything, identify which NIH institute is the best home for your project and read its priorities. The right institute fit can make or break a review.
Typical budgets and durations
NIH publishes statutory budget guidelines (hard-dollar ceilings) that are adjusted periodically, so treat these as recent-cycle figures and confirm the current numbers on seed.nih.gov before budgeting.
| Phase | Recent guideline (verify) | Typical duration | Purpose |
|---|---|---|---|
| Phase I | Up to ~$323,000 total costs | ~6 months to 1 year | Establish technical merit and feasibility |
| Phase II | Up to ~$2.15 million total costs | Up to ~3 years | Full R&D toward a commercial product |
| Fast-Track | Combined Phase I + II | Spans both | One application for both phases |
A few nuances unique to NIH:
- "Total costs" includes the fee. NIH budget caps cover direct costs, indirect (facilities and administrative) costs, and the small-business fee together.
- Waivers exist for certain topics. NIH has SBA-approved waivers letting specific topics exceed the standard caps (Phase I budgets above the guideline and Phase II meaningfully higher). If you think your project needs more, contact the relevant institute's SBIR/STTR program staff before submitting - exceeding the cap without justification or a waiver risks rejection.
- Direct Phase II exists for some institutes, letting select applicants skip Phase I when they already have feasibility data - but availability and rules vary by institute, so verify.
Eligibility
NIH applies the standard federal SBIR/STTR eligibility rules. Your company must:
- Be a for-profit small business located in the United States.
- Have 500 or fewer employees, including affiliates.
- Be more than 50% owned and controlled by U.S. citizens or permanent residents (or by another qualifying U.S.-owned small business).
- Perform the SBIR/STTR work primarily in the U.S.
For SBIR, the Principal Investigator's primary employment (more than 50%) must be with the small business. For STTR, you must have a formal partnership with a U.S. research institution, and the PI may be employed by either party - with required minimum work-share splits between the company and the partner.
Confirm the precise ownership, affiliation, and size definitions in the official NIH small business eligibility guidance and sbir.gov eligibility rules before relying on eligibility.
Clinical-trial considerations
This is where health-sector SBIR differs sharply from other agencies. NIH treats clinical trials as a defining structural choice:
- NIH publishes parallel versions of its omnibus solicitations - one "Clinical Trial Required" and one "Clinical Trial Not Allowed" (and sometimes "Optional").
- You must apply under the version that matches whether your project includes an NIH-defined clinical trial. Applying under the wrong one can render your application non-compliant before review.
- NIH's definition of a clinical trial is broad and may capture studies founders wouldn't intuitively call a "trial." If you involve human participants in any prospective study, check NIH's clinical-trial definition carefully.
- Human-subjects work brings additional requirements: IRB approval, human-subjects protections, and (for trials) registration and reporting obligations.
When in doubt, contact NIH program staff early to confirm whether your study counts as a clinical trial and which solicitation applies.
Timeline
A realistic NIH SBIR/STTR path looks like this:
- Identify the right institute and decide omnibus vs targeted.
- Confirm the correct funding opportunity - including the clinical-trial version.
- Register in required systems (SAM.gov, eRA Commons, SBA Company Registry, Grants.gov). Start early; registrations can take weeks.
- Write and submit by a standard due date.
- Two-level peer review (study section, then advisory council) - typically several months.
- Award and Phase I work - feasibility, usually within a year.
- Apply for Phase II to fund full development.
From submission to award commonly takes around 8-9 months or more, so plan your runway accordingly. NIH uses recurring standard due dates; confirm the exact dates on seed.nih.gov for your cycle.
Freshness caveat: This page was last updated on 2026-06-16. Note that congressional SBIR/STTR authorization lapsed on September 30, 2025 and was restored in early 2026. NIH budget guidelines, due dates, and solicitations change between cycles - always verify the live solicitation on seed.nih.gov before submitting.
Bottom line for health and biotech founders
NIH SBIR/STTR is the deepest pool of non-dilutive R&D funding available to U.S. life-science startups. The keys to using it well: pick the right institute, choose the correct solicitation (especially the clinical-trial version), budget within the current statutory guidelines (or secure a waiver), and start your registrations early.
If your technology is science-based but not specifically health-focused, also compare the NSF SBIR program, which is innovation-driven and topic-agnostic. For a step-by-step application walkthrough, see how to apply for SBIR.